My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 376

    1.

    Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes.

    Krzyzanowska K, Mittermayer F, Wolzt M, Schernthaner G.

    Diabetes Care. 2007 Jul;30(7):1834-9. Epub 2007 Apr 24.PMID: 17456842 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease.

    Mittermayer F, Krzyzanowska K, Exner M, Mlekusch W, Amighi J, Sabeti S, Minar E, Müller M, Wolzt M, Schillinger M.

    Arterioscler Thromb Vasc Biol. 2006 Nov;26(11):2536-40. Epub 2006 Aug 24.PMID: 16931791 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study.

    Schnabel R, Blankenberg S, Lubos E, Lackner KJ, Rupprecht HJ, Espinola-Klein C, Jachmann N, Post F, Peetz D, Bickel C, Cambien F, Tiret L, Münzel T.

    Circ Res. 2005 Sep 2;97(5):e53-9. Epub 2005 Aug 11.PMID: 16100045 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Elevated plasma concentrations of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine predict adverse events in patients undergoing noncardiac surgery.

    Maas R, Dentz L, Schwedhelm E, Thoms W, Kuss O, Hiltmeyer N, Haddad M, Klöss T, Standl T, Böger RH.

    Crit Care Med. 2007 Aug;35(8):1876-81.PMID: 17581491 [PubMed - indexed for MEDLINE]Related articles

    5.

    Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy.

    Lajer M, Tarnow L, Jorsal A, Teerlink T, Parving HH, Rossing P.

    Diabetes Care. 2008 Apr;31(4):747-52. Epub 2007 Dec 27.PMID: 18162497 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes.

    Tarnow L, Hovind P, Teerlink T, Stehouwer CD, Parving HH.

    Diabetes Care. 2004 Mar;27(3):765-9.PMID: 14988299 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention.

    Lu TM, Ding YA, Lin SJ, Lee WS, Tai HC.

    Eur Heart J. 2003 Nov;24(21):1912-9.PMID: 14585249 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Asymmetric dimethylarginine enhances cardiovascular risk prediction in patients with chronic heart failure.

    Dückelmann C, Mittermayer F, Haider DG, Altenberger J, Eichinger J, Wolzt M.

    Arterioscler Thromb Vasc Biol. 2007 Sep;27(9):2037-42. Epub 2007 Jun 14.PMID: 17569878 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Asymmetric dimethylarginine, smoking, and risk of coronary heart disease in apparently healthy men: prospective analysis from the population-based Monitoring of Trends and Determinants in Cardiovascular Disease/Kooperative Gesundheitsforschung in der Region Augsburg study and experimental data.

    Maas R, Schulze F, Baumert J, Löwel H, Hamraz K, Schwedhelm E, Koenig W, Böger RH.

    Clin Chem. 2007 Apr;53(4):693-701. Epub 2007 Feb 22.PMID: 17317881 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study).

    Meinitzer A, Seelhorst U, Wellnitz B, Halwachs-Baumann G, Boehm BO, Winkelmann BR, März W.

    Clin Chem. 2007 Feb;53(2):273-83. Epub 2006 Dec 21.PMID: 17185364 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Relationship of baseline plasma ADMA levels to cardiovascular outcomes at 2 years in men with acute coronary syndrome referred for coronary angiography.

    Cavusoglu E, Ruwende C, Chopra V, Yanamadala S, Eng C, Pinsky DJ, Marmur JD.

    Coron Artery Dis. 2009 Mar;20(2):112-7.PMID: 19240644 [PubMed - indexed for MEDLINE]Related articles

    12.

    Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community.

    Böger RH, Sullivan LM, Schwedhelm E, Wang TJ, Maas R, Benjamin EJ, Schulze F, Xanthakis V, Benndorf RA, Vasan RS.

    Circulation. 2009 Mar 31;119(12):1592-600. Epub 2009 Mar 16.PMID: 19289633 [PubMed - indexed for MEDLINE]Related articles

    13.

    Asymmetric dimethylarginine, cortisol/cortisone ratio, and C-peptide: markers for diabetes and cardiovascular risk?

    Anderson JL, Carlquist JF, Roberts WL, Horne BD, May HT, Schwarz EL, Pasquali M, Nielson R, Kushnir MM, Rockwood AL, Bair TL, Muhlestein JB; Intermountain Heart Collaborative Study Group.

    Am Heart J. 2007 Jan;153(1):67-73.PMID: 17174641 [PubMed - indexed for MEDLINE]Related articles

    14.

    Asymmetric dimethylarginine is associated with macrovascular disease and total homocysteine in patients with type 2 diabetes.

    Krzyzanowska K, Mittermayer F, Krugluger W, Schnack C, Hofer M, Wolzt M, Schernthaner G.

    Atherosclerosis. 2006 Nov;189(1):236-40. Epub 2006 Jan 18.PMID: 16414052 [PubMed - indexed for MEDLINE]Related articles

    15.

    C-reactive protein predicts future cardiovascular events in patients with carotid stenosis.

    Schlager O, Exner M, Mlekusch W, Sabeti S, Amighi J, Dick P, Wagner O, Koppensteiner R, Minar E, Schillinger M.

    Stroke. 2007 Apr;38(4):1263-8. Epub 2007 Feb 22.PMID: 17322087 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Joint effects of C-reactive protein and glycated hemoglobin in predicting future cardiovascular events of patients with advanced atherosclerosis.

    Schillinger M, Exner M, Amighi J, Mlekusch W, Sabeti S, Rumpold H, Wagner O, Minar E.

    Circulation. 2003 Nov 11;108(19):2323-8. Epub 2003 Oct 13.PMID: 14557362 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Impact of asymmetric dimethylarginine on mortality after acute myocardial infarction.

    Zeller M, Korandji C, Guilland JC, Sicard P, Vergely C, Lorgis L, Beer JC, Duvillard L, Lagrost AC, Moreau D, Gambert P, Cottin Y, Rochette L.

    Arterioscler Thromb Vasc Biol. 2008 May;28(5):954-60. Epub 2008 Feb 14.PMID: 18276906 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Effect of nebivolol and metoprolol treatments on serum asymmetric dimethylarginine levels in hypertensive patients with type 2 diabetes mellitus.

    Oğuz A, Uzunlulu M, Yorulmaz E, Yalçin Y, Hekim N, Fici F.

    Anadolu Kardiyol Derg. 2007 Dec;7(4):383-7.PMID: 18065333 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Targeted metabolomic evaluation of arginine methylation and cardiovascular risks: potential mechanisms beyond nitric oxide synthase inhibition.

    Wang Z, Tang WH, Cho L, Brennan DM, Hazen SL.

    Arterioscler Thromb Vasc Biol. 2009 Sep;29(9):1383-91. Epub 2009 Jun 18.PMID: 19542023 [PubMed - indexed for MEDLINE]Related articles

    20.

    Prospective evaluation of the relationship between C-reactive protein, D-dimer and progression of peripheral arterial disease.

    Musicant SE, Taylor LM Jr, Peters D, Schuff RA, Urankar R, Landry GJ, Moneta GL.

    J Vasc Surg. 2006 Apr;43(4):772-80; discussion 780.PMID: 16616235 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity